CurrentCapital BluecrossPolicy MP 2.402

Esophagogastroduodenoscopy (EGD)

Customize your policy alerts

Sign up for Capital Bluecross Policy MP 2.402 alerts

Get alerted when Policy MP 2.402 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines when diagnostic, therapeutic, and surveillance/periodic EGD is medically necessary, investigational, or not recommended; applies to products administered by Capital Bluecross with benefit variations noted.

Policy Summary

PayerCapital Bluecross

PolicyEsophagogastroduodenoscopy (EGD)

Policy CodePolicy MP 2.402

Change TypeNo material clinical or coverage changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionVerify medical necessity and member benefit coverage prior to performing listed EGD procedures; document clinical justification when criteria are met.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentCapital BluecrossPolicy MP 2.402

Esophagogastroduodenoscopy (EGD)

Customize your policy alerts

Sign up for Capital Bluecross Policy MP 2.402 alerts

Get alerted when Policy MP 2.402 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerCapital Bluecross

PolicyEsophagogastroduodenoscopy (EGD)

Policy CodePolicy MP 2.402

Change TypeNo material clinical or coverage changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionVerify medical necessity and member benefit coverage prior to performing listed EGD procedures; document clinical justification when criteria are met.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

coveredtypes of EGD use included

multiple schedulessurveillance guidance examples

functional & routine screeninginvestigational exclusions

3related policies

68.3%CLE sensitivity (per-lesion)

Coverage Criteria for Esophagogastroduodenoscopy (EGD)

Medically Necessary Indications

EGD is covered when ANY of the following diagnostic, therapeutic, or surveillance criteria are met:

Covered Indications: As the initial method of evaluation of symptoms as an alternative to radiographic studies; following an unsuccessful empirical trial of therapy for a suspected benign digestive disorder (e.g., PPI for reflux) when symptoms persist; when a change in management is probable based on EGD results; when a primary therapeutic procedure is contemplated; persistent upper abdominal distress despite appropriate therapy; upper abdominal distress associated with signs suggesting structural disease or new-onset symptoms >50 years; dysphagia or odynophagia; reflux symptoms that persist or recur despite appropriate therapy; persistent unexplained vomiting; systemic diseases where upper GI pathology might modify planned management (e.g., candidates for organ transplantation, long-term anticoagulation, chronic NSAID therapy, head and neck cancer); familial adenomatous polyposis syndromes; confirmation and histologic diagnosis of radiographically demonstrated lesions (suspected neoplasm, gastric/esophageal ulcer, upper tract stricture/obstruction); active or recent GI bleeding (including when surgical therapy is contemplated, re-bleeding after prior therapy, suspected portal hypertension or aortoenteric fistula, or unexplained iron deficiency anemia when an upper source is suspected or colonoscopy is nondiagnostic); sampling of duodenal or jejunal tissue or fluid; assessment after caustic agent ingestion; evaluation for suspected small-bowel disease (e.g., celiac disease); intraoperative evaluation of anatomic reconstructions after foregut surgery (e.g., anastomotic leak, fundoplication, pouch configuration during bariatric surgery); and pernicious anemia 6 months after diagnosis or with upper GI symptoms; therapeutic indications include variceal therapy for portal hypertension/cirrhosis, endoscopic treatment of bleeding lesions, foreign body removal, removal of selected lesions, esophageal stricture dilation/management of achalasia (including botulinum toxin or balloon dilation), placement of feeding or drainage tubes, dilation and stenting of stenotic lesions, palliative therapy of stenosing neoplasms, endoscopic therapy of intestinal metaplasia, and management of operative complications (e.g., dilation or stenting of anastomotic strictures, leaks, or fistulae).

See source chunks for full itemized indications.

Surveillance / Periodic EGD

Surveillance/premalignant condition schedules and example intervals:

Barrett esophagus surveillance: Barrett esophagus without dysplasia: every 3–5 years. Indeterminate for dysplasia: repeat EGD to clarify presence and grade of dysplasia. Low-grade dysplasia (LGD): repeat EGD in 6 months to confirm LGD, then annually. High-grade dysplasia (HGD): every 3 months for 1 year; after 1 year with no cancer detected, extend intervals.

Intervals vary by findings; follow-up individualized for HGD.

Other premalignant and hereditary conditions: Caustic ingestion: begin surveillance 15–20 years after injury, then every 1–3 years. Tylosis: begin at age 30, every 1–3 years. Gastric epithelial (adenomatous) polyps: first surveillance at 1 year after removal; if negative, then every 3–5 years; high-grade dysplasia or early gastric cancer—individualize intervals. Familial adenomatous polyposis (FAP)/HNPCC: begin at time of colectomy or after age 30; if no adenomas, repeat in 5 years; duodenal/periampullary adenomas: intervals based on disease stage; papillary adenomas after advanced adenomas/dysplasia: every 6 months for ≥2 years, then every 3 years. MALT lymphoma: every 3–6 months for first 2 years after H. pylori eradication, then every 6–12 months.

Surveillance intervals differ by condition and pathology.

Investigational / Not Supported Indications

EGD is considered investigational (insufficient evidence) for the following indications:

Investigational Indications: Evaluation of symptoms considered functional in origin after extensive evaluation (no physiologic cause found); metastatic adenocarcinoma of unknown primary when EGD results will not alter management; radiographic findings alone such as asymptomatic or uncomplicated sliding hiatal hernia, uncomplicated duodenal bulb ulcer that has responded to therapy, or deformed duodenal bulb when asymptomatic or responsive to therapy; routine preoperative EGD prior to bariatric surgery in asymptomatic individuals; routine screening in asymptomatic individuals; screening or evaluation of colorectal cancer in patients without FAP. Sequential or periodic EGD is investigational for surveillance for malignancy in gastric atrophy, pernicious anemia, fundic gland or hyperplastic polyps, gastric intestinal metaplasia, prior benign gastric operations; surveillance of healed benign disease (esophagitis, gastric or duodenal ulcer); repeat EGD after a prior normal study if symptoms are unchanged; and surveillance after adequate sampling or removal of nondysplastic gastric polyps.

These indications are described in the policy as investigational due to insufficient evidence.

Adjunctive CLE for BE surveillance

Evidence summary and guidance for confocal laser endomicroscopy (CLE) as an adjunct in Barrett esophagus (BE) surveillance:

Evidence and guideline summary: Randomized trials and meta-analyses demonstrate that CLE/pCLE can increase sensitivity for detection of intestinal metaplasia, dysplasia, and HGD/early carcinoma in some study settings (e.g., reported per-lesion sensitivities ~68% and per-individual increases in sensitivity when CLE is added), and may reduce the median number of biopsies per individual compared with four-quadrant random biopsies. However, CLE may reduce specificity relative to white-light endoscopy, results vary across studies and settings, and a meta-analysis concluded CLE is not an acceptable replacement for four-quadrant biopsy for diagnosis of HGD/adenocarcinoma in BE. Major society guidelines (AGA, ASGE, ACG) continue to recommend four-quadrant random (Seattle protocol) biopsies for routine BE surveillance and do not recommend routine use of CLE; CLE may have a role in specialized centers or high-prevalence settings to target biopsies but is not supported as a routine substitute for the Seattle protocol.

Document cites multicenter randomized trials, crossover trials, meta-analyses, and society guideline statements.

Additional explanatory notes: Routine screening in asymptomatic individuals and multiple listed surveillance scenarios are identified in the policy as investigational due to insufficient evidence. Examples called out include surveillance for malignancy in gastric atrophy, pernicious anemia, fundic gland or hyperplastic polyps, gastric intestinal metaplasia, prior gastric operations for benign disease, surveillance of healed benign disease (for example esophagitis or healed ulcers), and repeat EGD after a prior normal study when symptoms are unchanged. The policy also lists specific radiographic findings and preoperative scenarios (e.g., prior to bariatric surgery in asymptomatic individuals) as investigational when they would not alter management.

Guideline positions on routine confocal laser endomicroscopy (CLE) use for Barrett's esophagus (BE) surveillance are summarized as follows: national societies continue to endorse the Seattle four-quadrant random biopsy protocol as the standard for surveillance. The 2016 AGA update stated that CLE "cannot be recommended in the routine clinical management" of BE surveillance. The 2019 ASGE guideline recommends against routine use of CLE compared with white-light endoscopy plus Seattle protocol biopsies. The 2022 ACG update noted CLE may assist targeting biopsies in centers with high prevalence of neoplasia, but did not endorse routine use or a recommendation for white light plus CLE.

Note: the provided document chunks do not include a separate, explicit list labeled as coverage exclusions beyond the investigational and not-supported indications already incorporated into the policy text and surveillance listings. The policy history and administrative footer are present but no standalone exclusion table appears in the cited extracts.

Examples of indications the policy designates as investigational or not supported include evaluation of symptoms considered functional in origin after extensive evaluation, routine screening in asymptomatic individuals, and performing EGD prior to bariatric surgery in asymptomatic individuals. The policy also lists radiographic findings unlikely to change management (for example asymptomatic sliding hiatal hernia or a deformed duodenal bulb when asymptomatic) and multiple surveillance scenarios such as surveillance for malignancy in gastric atrophy or repeat EGD after a prior normal study if symptoms are unchanged.

CLE should not replace the Seattle protocol for routine Barrett's esophagus surveillance. National practice guidelines continue to recommend four-quadrant random biopsies as the standard surveillance approach, and both AGA and ASGE specifically advise that CLE is not recommended for routine clinical management or should be avoided as a routine substitute for Seattle protocol sampling.

Absence of explicit 'not medically necessary' statements: within the provided chunks there are no standalone headings or boxed statements explicitly labeled "not medically necessary." Instead, the policy conveys noncoverage or investigational status through the investigational and surveillance listings and wording in the policy sections; the document footer and policy history are present but do not contain an explicit separate 'not medically necessary' declaration in the cited extracts.

Procedure and Product Coding

Product-specific references (FEP)mixed

No codes listed

Covered when medically necessary (procedure codes listed)CPTCovered

43242	Esophagogastroduodenoscopy (EGD) diagnostic (listed among covered when medically necessary)
43235	EGD with biopsy (listed paired with 43242)
43243	EGD with removal of tumor, polyp, or other lesion; with mucosal resection (listed)
43236	EGD with control of bleeding, cautery or injection (listed)
43244	EGD with dilation (listed)
43237	EGD with foreign body removal (listed)
43245	EGD with other therapeutic intervention (listed)
43238	EGD with stent placement or removal (listed)
43246	EGD with complex therapeutic procedures (listed)
43239	EGD with additional procedures (listed)

1–10 of 22

1/3

Provider Actions, Authorization, and Documentation

Prior Authorization

Product-specific applicability — check product manual

This policy applies only to certain Capital Blue Cross programs and products; member-specific benefit variations may apply. The FEP PPO program refers to the FEP medical policy manual at fepblue.org for its policies.

Policy applicability varies by product; check product-specific manuals (e.g., FEP PPO).

Prior Authorization

Verify coverage and prior authorization before scheduling

Verify member benefits and medical necessity prior to scheduling EGD; the presence of CPT codes in the coding section does not guarantee coverage and prior authorization may be required per member benefit.

Confirm medical necessity and member-specific coverage before service.
Prior authorization may be required based on the member’s benefit plan.

Background and Evidence Context

Background: An esophagogastroduodenoscopy (EGD) is an endoscopic procedure using a flexible tube with a camera to visualize the esophagus, stomach, and duodenum. EGD permits direct inspection, targeted biopsy, and therapeutic interventions such as hemostasis for bleeding lesions, dilation of strictures, removal of foreign bodies or polyps, and placement of feeding or drainage tubes. It is used for diagnostic evaluation of persistent upper abdominal symptoms, dysphagia, suspected neoplasia, refractory reflux, unexplained vomiting, and for therapeutic management when endoscopic treatment is anticipated.

Definitions and Key Terms

EGD (Esophagogastroduodenoscopy) — Definition and description

DefinitionEsophagogastroduodenoscopy (EGD) is an upper gastrointestinal endoscopy using a thin, flexible endoscope to visualize the esophagus, stomach, and duodenum and to perform diagnostic and therapeutic interventions (e.g., biopsy, coagulation, dilation, foreign body removal).

Alternate nameAlso called upper GI endoscopy.

Key capabilitiesProvides visualization via a camera and allows passage of instruments for tissue sampling, hemostasis, dilation, and device placement.

Common indicationsEvaluation of persistent abdominal symptoms, dysphagia/odynophagia, GI bleeding, refractory reflux, and suspected neoplasm; therapeutic uses include variceal therapy, dilation, and lesion removal.

Barrett esophagus surveillance intervals — by dysplasia status

No dysplasia

Policy Revision History

2026-07-01policy_effective_dateLatest

Policy MP 2.402 (Esophagogastroduodenoscopy) became effective on 2026-07-01.

Policy Summary

PayerCapital Bluecross

PolicyEsophagogastroduodenoscopy (EGD)

Policy CodePolicy MP 2.402

Change TypeNo material clinical or coverage changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionVerify medical necessity and member benefit coverage prior to performing listed EGD procedures; document clinical justification when criteria are met.

SourceLink

On This Page

Prior Authorization

Prior authorization not specified in policy text

No specific prior authorization requirements are specified in the provided policy text; however, prior authorization requirements may still apply per member benefit or specific product.

Policy text contains no explicit prior authorization rules in these chunks.
Check member benefit for prior authorization requirements.

Step Therapy

Document prior unsuccessful empirical therapy before diagnostic EGD

For suspected benign disorders (for example reflux), ensure documentation shows an appropriate trial of empirical therapy (e.g., proton‑pump inhibitor) was unsuccessful before diagnostic EGD is pursued.

Upper abdominal distress: persists despite an appropriate trial of therapy (e.g., PPI).
Esophageal reflux symptoms that persist or recur despite appropriate therapy are listed as covered indications.

Step Therapy

Limit imaging adjuncts; use Seattle protocol as standard for BE surveillance

Follow guideline-preferred Seattle four‑quadrant random biopsy protocol for Barrett’s esophagus surveillance; confocal laser endomicroscopy (CLE) is not recommended for routine replacement of the Seattle protocol and should be limited to select centers/settings.

National guidelines recommend four‑quadrant random biopsies for BE surveillance.
ASGE recommends against routine CLE compared with white‑light plus Seattle protocol.
Trials show CLE increases sensitivity but is not consistently superior and reduces biopsy counts.

Note

No step therapy specified

The policy does not describe any step therapy requirements in the provided sections.

No step therapy requirements are described in these chunks.

Documentation Required

Provide clinical justification to support medical necessity

Document clinical justification demonstrating medical necessity: persistent symptoms despite appropriate therapy, signs suggesting structural disease, history of GI bleeding, or situations where EGD results would change management.

Persistence of symptoms despite appropriate trial of therapy (e.g., PPI).
Signs suggesting structural disease (weight loss, anorexia, new‑onset >50 years).
When EGD results would probably change management (e.g., preoperative planning, suspected neoplasm).

Documentation Required

Document procedure details and biopsy counts if using CLE instead of Seattle protocol

When CLE is used instead of the Seattle four‑quadrant biopsy protocol, document the specific indication, the imaging/technique used (CLE vs Seattle protocol), and the number and locations of biopsies with final pathologic correlation.

Document indication for CLE in lieu of standard biopsies.
Record technique (CLE vs four‑quadrant biopsies) and biopsy counts/locations and correlate with pathology.

Denial Risk

Denial risk for investigational or routine screening indications

Claims for EGD performed for investigational or unsupported indications (for example evaluation of functional symptoms without physiologic findings, routine asymptomatic screening, or pre‑bariatric surgery in asymptomatic individuals) are at risk for denial.

Investigational indications include evaluation of functional symptoms after extensive evaluation, routine screening in asymptomatic individuals, and pre‑bariatric surgery in asymptomatic individuals.
Sequential or periodic EGD for listed surveillance scenarios (e.g., gastric atrophy, pernicious anemia, gastric intestinal metaplasia) is considered investigational.

Denial Risk

Coverage depends on member benefits and medical necessity

Coverage of listed procedure codes is contingent on member benefit and medical necessity; the presence of a code in the coding section does not guarantee coverage and claims may be denied if not covered by the member’s plan or not medically necessary.

Identification of a code does not denote coverage; coverage is determined by member benefit information.
Claims are adjudicated based on medical necessity and the member’s benefit plan.

Note

No explicit authorization/denial triggers in policy text

No explicit authorization or denial triggers are specified in the provided policy chunks; follow member benefit and utilization management procedures for authorization decisions.

Policy history/footer present; no explicit authorization/denial triggers in these chunks.
Adhere to product‑specific authorization processes as applicable.

Surveillance EGD every 3 to 5 years.

Indeterminate for dysplasiaRepeat EGD to clarify presence and grade of dysplasia.

Low-grade dysplasia (LGD)Repeat EGD in 6 months to confirm LGD, then annually.

High-grade dysplasia (HGD)EGD every 3 months for 1 year; after 1 year with no cancer detection, lengthen intervals thereafter.

Seattle protocol — four-quadrant random biopsy strategy

DefinitionSeattle protocol is a surveillance biopsy strategy for Barrett's esophagus using four-quadrant random biopsies along the Barrett's segment at specified intervals (every 1–2 cm for surveillance; 1 cm if neoplasia suspected).

Role in trialsUsed as the reference standard biopsy protocol in randomized trials comparing advanced imaging modalities to standard surveillance.

Guideline statusMajor GI society guidelines continue to recommend four-quadrant random biopsies (Seattle protocol) for routine BE surveillance.

Confocal laser endomicroscopy (CLE) / pCLE — Definition and role

DefinitionConfocal laser endomicroscopy (CLE), including probe-based CLE (pCLE), is an advanced endoscopic imaging technique that provides real-time microscopic visualization of the mucosa to target biopsies and assess tissue for intestinal metaplasia, dysplasia, and early carcinoma.

Intended roleMay be used to target biopsies and provide real-time mucosal assessment during BE surveillance, potentially reducing the number of random biopsies required.

Performance characteristicsStudies report increased sensitivity for detecting HGD/early carcinoma when CLE is added to white-light endoscopy (e.g., sensitivity improvements reported), but specificity may be lower versus white-light alone.

Use contextBenefits observed primarily in experienced centers and select high-prevalence settings; not universally superior to Seattle-protocol white-light biopsy sampling.

Confocal laser endomicroscopy — evidence, study context, and guideline perspective

Supporting evidenceRandomized multicenter trials (e.g., Canto et al. 2014) and other RCTs report higher per-individual sensitivity with white-light endoscopy plus CLE versus white-light with random biopsy, and meta-analyses show increased per-lesion sensitivity but variable specificity.

Biopsy impactTrials report fewer median biopsies per individual with CLE-guided targeted biopsy (median 2) versus white-light with Seattle protocol (median 4).

Guideline recommendationsGuidelines (AGA, ASGE, ACG) do not recommend routine CLE in lieu of Seattle protocol; ASGE recommends against routine CLE compared with white-light plus Seattle protocol; ACG notes potential utility in high-prevalence centers.

Practical implicationCLE may be considered as an adjunct in specialized centers or select high-prevalence settings but should not replace four-quadrant random biopsies for routine surveillance.

Barrett's esophagus — definition and surveillance indication

DefinitionBarrett's esophagus (BE) is a premalignant condition of the distal esophagus characterized by intestinal metaplasia and is a common indication for surveillance EGD.

Surveillance rationaleSurveillance intervals are guided by dysplasia status to detect progression to dysplasia or early carcinoma when endoscopic therapy may alter management.

Associated guidelines and referencesManagement and surveillance recommendations are summarized in ACG, ASGE, and AGA guidance cited in the policy and supporting literature.